CYP2D6 Polymorphisms and Atypical Antipsychotic Weight Gain
Document Type
Article
Publication Date
4-15-2002
Description
Reports have linked atypical antipsychotics (AAPs) with weight gain. The polymorphic CYP2D6 involved in metabolism has been associated with medication morbidity. Eleven subjects receiving olanzapine were genotyped for CYP2D6 to examine the relationship between 2D6 and AAP weight gain. Using a linear regression, the dependent variable was percent change in body mass index (BMI). Genotype, dose and duration of treatment were independent. Genotype was significant (P < 0.0097) for those with a *1/*3 or *4 genotype experiencing a larger percent BMI change than those with a *1/*1 genotype. This may be due to increased olanzapine concentrations leading to increased exposure, which may trigger AAP weight gain.
Citation Information
Ellingrod, Vicki L.; Miller, Del; Schultz, Susan K.; Wehring, Heidi; and Arndt, Stephan. 2002. CYP2D6 Polymorphisms and Atypical Antipsychotic Weight Gain. Psychiatric Genetics. Vol.12(1). 55-58. https://doi.org/10.1097/00041444-200203000-00008 PMID: 11901361 ISSN: 0955-8829